Free Trial

Terumo (OTCMKTS:TRUMY) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Terumo logo with Medical background

Key Points

  • Terumo reported a quarterly earnings per share of $0.20, exceeding the consensus estimate of $0.17 by $0.03.
  • The company generated $1.76 billion in revenue during the quarter, slightly below analysts' expectations of $1.80 billion.
  • Following the earnings announcement, Terumo's shares fell 0.4%, bringing the stock price to $18.60.
  • Need better tools to track Terumo? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Terumo (OTCMKTS:TRUMY - Get Free Report) posted its earnings results on Thursday. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.03, Zacks reports. Terumo had a net margin of 12.09% and a return on equity of 9.30%. The firm had revenue of $1.76 billion during the quarter, compared to analyst estimates of $1.80 billion.

Terumo Trading Down 0.4%

Shares of TRUMY stock traded down $0.07 on Friday, hitting $18.60. 96,442 shares of the stock traded hands, compared to its average volume of 199,910. The firm's 50-day moving average price is $17.51 and its two-hundred day moving average price is $18.26. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.78 and a current ratio of 3.00. The stock has a market capitalization of $27.54 billion, a PE ratio of 32.63 and a beta of 0.80. Terumo has a twelve month low of $15.95 and a twelve month high of $21.22.

Terumo Company Profile

(Get Free Report)

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

Further Reading

Earnings History for Terumo (OTCMKTS:TRUMY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Terumo Right Now?

Before you consider Terumo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terumo wasn't on the list.

While Terumo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines